| [1] | Galldiks N., Langen K.J., Albert N.L., et al. (2019). PET imaging in patients with brain metastasis—report of the RANO/PET group. Neuro. Oncol. 21:585−595. DOI:10.1093/neuonc/noz003 |
| [2] | Galldiks N., Lohmann P., Aboian M., et al. (2025). Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas. Lancet Oncol. 26:e436−e447. DOI:10.1016/S1470-2045(25)00193-7 |
| [3] | Katsanos A.H., Alexiou G.A., Fotopoulos A.D., et al. (2019). Performance of 18F-FDG, 11C-methionine, and 18F-FET PET for glioma grading: A meta-analysis. Clin. Nucl. Med. 44:864−869. DOI:10.1097/RLU.0000000000002654 |
| [4] | Treglia G., Muoio B., Trevisi G., et al. (2019). Diagnostic performance and prognostic value of PET/CT with different tracers for brain tumors: A systematic review of published meta-analyses. Int. J. Mol. Sci. 20:4669. DOI:10.3390/ijms20194669 |
| [5] | Albert N.L., Galldiks N., Ellingson B.M., et al. (2024). PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): A report of the RANO group. Lancet Oncol. 25:e29–e41. DOI:10.1016/S1470-2045(23)00525-9. |
| Li D., Zhao Q., Zhao Z., et al. (2026). Practice guidelines for amino acid PET in gliomas. The Innovation Oncology 1:100020. https://doi.org/10.59717/j.xinn-oncol.2026.100020 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Guidelines of amino acid PET for gliomas.